February 2026 Research Update

Imaging and lab tests are being refined for diagnosis

This month, several studies pointed in the same direction: PSP can look like other movement disorders, and new measurement tools may help separate them more reliably, but most approaches are still in early testing. Across different imaging types, the strongest results came from combining more than one kind of information rather than relying on a single measure. The common theme is improved pattern recognition, with a clear need for validation in broader real-world settings. [1] [2] [3]

On standard MRI, an automated system that used both cortical (outer brain) features and subcortical (deep brain) shape features separated PSP from similar conditions better than either feature set alone. In that dataset, the combined approach reached 86.1% accuracy when distinguishing Parkinson's disease, PSP, and corticobasal syndrome. This supports the idea that PSP leaves a multi-region brain "fingerprint" that computers can help detect. [1]

In diffusion MRI (a scan that measures microstructure of white matter), neurite-density measures were reported as the most useful for distinguishing PSP-Richardson syndrome (PSP-RS) from Parkinson's disease and from controls. The pattern in PSP-RS centered on brainstem and related pathways, while corticobasal syndrome showed a different pattern in movement-related tracts closer to the brain surface. The study also noted that adjusting for "free water" changed some group differences, showing that technical choices can affect what a scan appears to show. [3]

PET imaging approaches also showed potential for separation, using different targets in the brain. A proof-of-concept analysis of dopamine-transporter PET reported better discrimination among Parkinson's disease, dementia with Lewy bodies, and PSP when two PET-derived maps were combined, compared with either alone. A separate small study using a synaptic-density PET tracer found lower synaptic density in PSP in the midbrain and deep brain regions, and reported that one region (left caudate) separated PSP from controls with an AUC of 0.94. [2] [4]

Not all promising diagnostic work is in living patients yet. A laboratory assay that amplifies tau "seeds" from postmortem brain tissue was able to separate PSP from other tau diseases by changing salt conditions and using different tau substrates, suggesting that tau diseases may have detectably different forms of tau. The authors noted that the next step is to see whether similar separation is possible in body fluids rather than brain tissue. [5]

Two studies highlighted why better tools matter: clinical labels can be wrong, and overlap syndromes are common. In an autopsy series, clinical diagnoses across neurodegenerative diseases were usually specific but had widely varying sensitivity, with PSP and corticobasal degeneration among the harder diagnoses to capture clinically. In a separate real-world cohort evaluated for corticobasal degeneration criteria, many people met more than one clinical phenotype, often including a PSP-like syndrome, showing how mixed the clinical picture can be. [6] [7]

What this means in day-to-day terms

The main change this month is growing evidence that multi-signal approaches (combining features within an MRI, or combining different PET-derived maps) may separate PSP from look-alike conditions better than single measurements. This does not prove any one test is ready to replace expert evaluation, because many studies were small or proof-of-concept and often need external validation. Still, it helps explain why diagnosis can be challenging and why research is focusing on more objective patterns that could eventually support clearer diagnosis and tracking. [1] [2]

An important uncertainty is whether these results will hold up across hospitals, scanners, and a wider range of patients, including earlier stages and mixed presentations. Some work is still limited to postmortem tissue, which is valuable for understanding disease differences but is not yet a practical test during life. The broader message is that PSP is being approached with multiple complementary "readouts" of the brain, and the field is actively testing which ones are most reliable. [5] [6]

Symptoms and brain changes linked to everyday function

This month added a clearer picture that PSP involves more than balance and stiffness, and that some symptoms may be tied to specific brain-system changes. Across studies, patient experience (vision-related daily functioning) and awareness of thinking difficulties stood out as areas where PSP can be especially impacted. Imaging work also linked gait and balance problems to loss of a key brain chemical system, providing a possible biological explanation for part of the movement disability. [8] [9] [10]

In a questionnaire study comparing several movement disorders, people with PSP reported the greatest vision-related quality-of-life problems, with the biggest deficits in visual processing speed. This puts numbers and structure around a common lived experience: vision issues can affect daily tasks in PSP even when the eyes themselves are not the main problem. The study did not test a treatment, but it helps define which visual difficulties are most burdensome. [8]

A separate study found that people with PSP showed more executive anosognosia than people with Parkinson's disease, meaning their self-report (and even informant report) tended to understate the degree of executive-function difficulty measured on objective testing. Subjective complaints were more strongly related to depressive symptoms than to measured executive performance. This helps explain why families and patients may sometimes have different impressions of cognitive or planning changes in PSP. [9]

In a small PET imaging study focused on gait and postural instability, lower cholinergic signal (a marker of loss of acetylcholine nerve terminals) was linked to worse gait and balance scores across many brain regions. The strongest contributions were reported in areas connected to memory and to brainstem-thalamus pathways, suggesting that loss of cholinergic inputs may be one contributor to the gait and balance syndrome in PSP. Because the study was cross-sectional, it cannot show whether these changes drive worsening over time. [10]

How to interpret these findings

These studies mainly add understanding rather than changing care right now. They help clarify that PSP-related disability can involve visual processing, insight into thinking changes, and brain-chemical systems beyond dopamine. The evidence here is observational, so it can show links but not prove cause-and-effect or predict what will happen for an individual person. [8] [10]

What remains uncertain is how these findings vary across PSP subtypes and across disease stages, since sample sizes were small in the imaging work. Even with that limitation, the month helps build a more complete mental model of PSP as a condition affecting multiple brain networks that influence walking, thinking, and visual functioning. [9] [10]

Early clues about tracking change over time

This month included two longitudinal studies that speak to a common patient question: what changes track progression in PSP and related conditions. The overall message was mixed: tau PET showed measurable increases in certain deep brain regions over time, but those imaging changes did not line up neatly with clinical change over the same period. In peripheral nerve testing, polyneuropathy was common in PSP, but clear progression of nerve signals was not seen in the PSP group in this small cohort. [11] [12]

In serial tau PET imaging over about 21 months, PSP participants showed increasing tau signal mainly in subcortical regions such as the globus pallidus and putamen. People with lower baseline tau signal tended to show larger increases, and the authors described a ceiling effect that may limit how much additional tau PET signal can rise in more advanced disease. The study also reported that tau changes followed functional brain networks, which is one possible way to explain how pathology spreads. [11]

Despite detectable tau PET increases, the study did not find a clear correlation between tau PET change and change in clinical severity scores over the same interval. In plain language, the scan signal moved, but it did not serve as a simple readout of day-to-day progression in this dataset. This is important for understanding what tau PET might and might not be able to measure in PSP. [11]

In a 2-year nerve conduction study of atypical parkinsonian syndromes, polyneuropathy was reported as common at baseline in both multiple system atrophy (MSA) and PSP. Over time, nerve signal decline was seen in the MSA group but not clearly in the PSP group, though the PSP sample was small. This suggests that peripheral nerve involvement may not progress in the same way across these disorders, or may be harder to detect in PSP with the measures used. [12]

At the population level, a registry study of frontotemporal lobar degeneration subtypes estimated incidence and survival, with PSP/CBS grouped together for some analyses. Median survival from diagnosis for the PSP/CBS group was 49.5 months in that region and time period. This provides context about typical disease course at a community level, while also reflecting the reality that registry diagnoses may include some misclassification. [13]

What this adds to the bigger picture

These findings may matter more in the future than right now, because they are about measurement rather than treatment. The tau PET study helps clarify that PSP-related tau signal can increase over time in deep brain regions, but it also underscores an uncertainty: imaging change does not automatically translate into a simple measure of how symptoms change. The nerve study adds a practical reminder that some people with PSP have peripheral nerve findings, but this small dataset did not show a clear worsening trend in PSP over 2 years. [11] [12]

The registry data provide a broader sense of expected timelines after diagnosis at a population level, which can complement individual clinical discussions. However, registry estimates do not capture every personal factor and can be influenced by diagnostic delay and diagnostic uncertainty. Taken together, the month strengthens the idea that PSP progression likely needs multiple kinds of tracking tools rather than a single number or scan readout. [13]

Preclinical efforts aimed at tau and related pathways

This month brought early, preclinical signals for ways researchers are trying to reduce tau-related damage, which is central to PSP biology. The studies were not in people with PSP, but they explored two different strategies: directly lowering tau levels and blocking a tau-relevant enzyme. A third experimental line suggested that stress-response differences could influence tau toxicity through a specific protein, offering another potential target to explore. [14] [15] [16]

In aged tau transgenic mice, delivering tau-targeting microRNAs into one frontal brain region after symptoms had started reduced tau measures in that region and improved performance on a memory task. The same work reported normalization of recorded brain-cell firing patterns and less tau buildup at presynaptic terminals, without obvious negative effects in the measures reported. This supports the idea that lowering tau even after symptom onset can change brain function in animal models. [14]

In several mouse models of neurodegeneration, the Dyrk1a inhibitor DYR533 was reported to reduce tau hyperphosphorylation and markers of inflammation, and to improve anxiety-like behavior and spatial memory. The summary did not specify PSP-only models, but it included a model with PSP-relevant tau pathology, framing this as a cross-disease approach to tau-related pathways. These results are encouraging as a research direction, but they do not predict how a drug will perform in PSP patients. [15]

In cellular and fly experiments linked with analysis of human PSP brain tissue, one PERK haplotype (PERK-B) allowed translation of DLX1 under stress conditions, and DLX1 appeared more detergent-insoluble in PSP brain tissue. Reducing the fly version of DLX1 lowered tau-related toxicity in vivo. This suggests a specific stress-response-to-tau pathway that could be studied further, but it remains early-stage biology rather than a tested therapy. [16]

How close is this to patient care?

All findings in this theme are laboratory or animal research, so they mainly matter as groundwork for future therapies rather than something that affects care now. They help clarify which biological levers might reduce tau-related problems, including lowering tau directly and targeting enzymes or stress-response pathways that influence tau toxicity. What remains uncertain is whether these strategies can be delivered safely and effectively across the human brain, and whether benefits would translate to PSP symptoms in people. [14] [15] [16]

What autopsy, genetics, and models suggest

This month reinforced that "PSP" can refer to a clinical syndrome with more than one possible underlying cause, and that the tau biology itself differs across related diseases. Postmortem work described PSP-specific features of small tau aggregates and cell vulnerabilities, while genetic and case reports highlighted situations where PSP-like symptoms occur alongside other pathologies or due to rare genetic disorders. These studies help explain why diagnosis and research grouping can be complicated. [17] [18] [19] [20]

In postmortem brain tissue, one study reported that small tau aggregates looked different across tau diseases, with PSP showing shorter, round aggregates and a specific phosphorylation site (Ser356). The same work reported that this Ser356 signal correlated with markers of inflammation and cell stress, and that aggregate properties aligned with disease-specific seeding profiles. This adds detail to the idea that tau in PSP is not identical to tau in Alzheimer's or other tauopathies. [17]

Another autopsy study focused on Von Economo neurons in the anterior cingulate cortex across FTLD-tau subtypes, including PSP. It reported no significant difference in this neuron density between CBD and PSP, while 4R tau cases had much higher density than 3R cases overall. This suggests that different tau isoforms may affect certain neuron populations differently, though it does not directly map to a specific symptom in PSP. [18]

A genetics study in a large Chinese parkinsonism cohort found rare DCTN1 variants associated with Perry disease, and noted that the clinical presentations could mimic PSP or early-onset Parkinson's disease. Functional work supported that these variants can disrupt cell processes and were linked to TDP-43 pathology. This highlights that a small number of people with PSP-like symptoms may have a different underlying disease mechanism. [19]

A genomic study of short tandem repeat expansions across neurodegenerative dementias found validated pathogenic expansions more often in dementia cases than controls, and reported a nominal enrichment of intermediate TBP alleles in PSP that did not remain significant after multiple testing. This suggests genetics may contribute to risk in a subset of people, but the specific PSP signal in this dataset remains uncertain. The study also emphasized that combining detection methods improved finding expansions in whole-genome data. [21]

Two case reports described PSP-related pathology in unusual contexts, emphasizing overlap rather than a single pure disease. One person had both dementia with Lewy bodies pathology and mild PSP pathology at autopsy, with early falls as a prominent feature. Another report described an aged macaque with spontaneous PSP-like 4R tau pathology and parkinsonism compared with a control macaque, suggesting a possible animal model for sporadic tauopathy research. [20] [22]

How to hold these results

These studies mainly help explain why PSP symptoms can overlap with other conditions and why research is paying close attention to the exact form of tau and other pathologies. The autopsy findings support the idea that PSP has distinguishing tau features, while genetics and case reports show that PSP-like symptoms can sometimes come from different biological causes or mixed brain pathologies. What remains uncertain is how often these mechanisms apply in typical PSP seen in clinic, since some reports are rare or based on small numbers. [17] [19] [20]